Quick Answer
Raphael Pharmaceutical Inc. reported Operating Income of -$1.25 million for fiscal year 2025.
Raphael Pharmaceutical Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$1.25M | +17.5% |
| 2024 | -$1.51M | -13.3% |
| 2023 | -$1.33M | +59.8% |
| 2022 | -$3.32M | -103.6% |
| 2021 | -$1.63M | -130.7% |
| 2020 | -$706.0K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$251.0K | +21.3% | +20.3% |
| June 30, 2025 | -$315.0K | -26.5% | +25.9% |
| March 31, 2025 | -$425.0K | +22.3% | -33.2% |
| September 30, 2024 | -$319.0K | +56.2% | -28.1% |
| June 30, 2024 | -$249.0K | +40.6% | +54.5% |
| March 31, 2024 | -$547.0K | -112.0% | +25.0% |
| September 30, 2023 | -$729.0K | +48.9% | -74.0% |
| June 30, 2023 | -$419.0K | +31.5% | -62.4% |
- Raphael Pharmaceutical Inc. showed an increase of +17.5% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Raphael Pharmaceutical Inc.’s operating income has declined by 76.3% (from -$706.0 thousand to -$1.25 million).
- The most recent figure is from Raphael Pharmaceutical Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: